[Editorial] Making treatment for obesity more equitable
Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
2026 may prove a pivotal year for obesity. GLP-1 receptor agonists have revolutionised obesity management over the past 10 years. Mounting evidence has established their benefits across many cardiometabolic and obesity-related conditions and the global weight-loss medications market is predicted to reach US$150 billion by 2035. More than a billion people live with obesity, with the burden rising rapidly in low-income and middle-income countries. High costs, limited production capacity, and supply-chain constraints have resulted in persistent inequitable access to GLP-1 receptor agonists.